DCGI orders withdrawal of AstraZeneca’s Olaparib tablets for gBRCA mutation and advanced ovarian cancer due to potential adverse effects. The drug was approved in 2018 for adult patients with ovarian cancer and certain breast cancers. DCGI orders withdrawal of AstraZeneca’s Olaparib tablets for gBRCA mutation and advanced ovarian cancer due to potential adverse effects. The drug was approved in 2018 for adult patients with ovarian cancer and certain breast cancers. Health and Fitness, Health Tips, Exercises & Workout Tips, Diet & Wellness | Times of India Lifestyle
India to withdraw AstraZeneca’s cancer drug due to adverse effects
